Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China

BACKGROUND: Fixed dose dual bronchodilators such as long-acting muscarinic antagonists (LAMAs) plus long-acting β2-agonists (LABAs) are a new and important inhaled preparation for COPD treatment in China. Among these, umeclidinium/vilanterol (UMEC/VIL) is increasingly being used in China, especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Ying, Yang, Nan, Wang, Yirong, Yang, Yujie, Xu, Min, He, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957300/
https://www.ncbi.nlm.nih.gov/pubmed/35345479
http://dx.doi.org/10.2147/COPD.S350218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957300/
https://www.ncbi.nlm.nih.gov/pubmed/35345479
http://dx.doi.org/10.2147/COPD.S350218

Ejemplares similares